Mylan will pay $1.6 billion to acquire Agila from Indian pharmaceutical company Strides Arcolab when the transaction closes in the fourth quarter of 2013.
DSK Legal, the Washington, DC, New York, Dallas and Orange County offices of Haynes and Boone LLP, the London office of Herbert Smith Freehills LLP, and Brazil’s Pinheiro Neto Advogados advised Strides for the deal, which was announced on 28 February.
The deal forms part of Mylan’s strategy to become one of the world’s three largest producers of injectable drugs, as well as to gain entry in to the Brazilian market, where Agila distributes its products and holds a number of assets, including manufacturing facilities.
Counsel to Mylan
Partners Nihar Mody and Gautam Bhat, and associates Soumit Mohapatra, Khusnuma Nagwaswalla, Jagriti Mohata, John Raghav and Lakshmi Krishnan in Mumbai
Skadden, Arps, Slate, Meagher & Flom LLP
Partners Marie Gibson, Eric Cochran, Erica Schohn, David Schwartz and Matthew Zisk in New York, partners Tim Sanders and Lorenzo Corte in London, partner Hal Hicks in Washington, DC and counsel Paul Doris in London
Barbosa Müssnich & Aragão
Partners Paulo Cezar Aragão and Roberto Dias Carneiro and associates Renata Maffei Pavie, Adriana Fuzinato, Niéje Carvalho, Fernanda Desio and Eduardo Carvalhaes in São Paulo
Slaughter and May in London
Counsel to Strides
DSK Legal in India
Herbert Smith Freehills LLP
Partners Alan Montgomery and Robert Moore in London
Haynes and Boone LLP
Partner Jeff Wolfson in Washington, DC, partner Lou Solomon in New York, partners Vicki Martin-Odette and Eric Williams in Dallas, of counsel Evert Tu in Orange County, of counsel Jennifer Wisinski in Dallas, and associates Alex Grishman and Chris Perez in New York
Pinheiro Neto Advogados
Partner Miguel Tornovsky and associates Caue Myanaki and Julia Durigan in São Paulo